{"id":49467,"date":"2022-10-11T11:02:00","date_gmt":"2022-10-11T09:02:00","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/"},"modified":"2022-10-11T11:02:00","modified_gmt":"2022-10-11T09:02:00","slug":"omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/","title":{"rendered":"Omniose Awarded $3.6 Million Grant from NIH to Develop Vaccines against Klebsiella pneumoniae"},"content":{"rendered":"
\n

BOSTON & ST. LOUIS–(BUSINESS WIRE)–Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, has been awarded a $3.6 million grant for the development of a Klebsiella pneumoniae<\/i> vaccine from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health. Klebsiella pneumoniae<\/i> is a leading cause of life-threatening sepsis in newborns1<\/sup> as well as healthcare-associated infections, including pneumonia, bloodstream infections, wound or surgical site infections, and meningitis2<\/sup>. Klebsiella<\/i> pneumoniae<\/i> has developed resistance to many classes of antimicrobials and was attributed to or associated with an estimated 600,000 deaths globally in 20193<\/sup>.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are grateful for the continued support from the NIH and look forward to further developing our multivalent bioconjugate vaccines targeting both the capsular and O-antigen polysaccharides of Klebsiella pneumoniae<\/i>,\u201d said Christian Harding, Ph.D., Chief Scientific Officer and co-founder of Omniose (previously known as VaxNewMo). Timothy Cooke, CEO, added \u201cThis NIH grant funding allows Omniose to extend our on-going efforts to combat serious infections due to Klebsiella<\/i>.\n<\/p>\n

\nOmniose Approach to Klebsiella pneumoniae<\/i> Vaccine<\/span>\n<\/p>\n

\nOmniose is utilizing its proprietary bioconjugation platform to develop novel polysaccharide protein conjugate vaccines targeting K. pneumoniae<\/i>4<\/sup>. K. pneumoniae<\/i> produces multiple surface polysaccharides, including a capsular polysaccharide (capsule) and a lipopolysaccharide decorated with an O-antigen polysaccharide (O-antigen). Both capsule and the O-antigen are known K. pneumoniae <\/i>virulence factors and were previously identified as potential vaccine candidates. Funds from this award as well as other NIH grants awarded to Omniose will support the development and IND-enabling studies of bioconjugate vaccines that target the most clinically relevant capsular polysaccharides and O-antigen polysaccharides of K. pneumoniae.<\/i>\n<\/p>\n

\nAbout Omniose<\/span>\n<\/p>\n

\nThe Omniose bioconjugate vaccine platform enables the precise enzymatic attachment of virtually any bacterial polysaccharide (sugar) antigen to engineered carrier proteins within a single E. coli <\/i>cell. Bioconjugation is a much simpler process than conventional chemical conjugation methods and has the potential to produce higher quality vaccines. However, the enzymes used for bioconjugation thus far could only address a limited range of bacterial targets. Omniose is breaking through this barrier by expanding the range of bacterial vaccines that can be developed, while leveraging the already established benefits of bioconjugation.\n<\/p>\n\n\n\n\n\n\n
References<\/span><\/td>\n<\/tr>\n
\n

\n1\n<\/p>\n<\/td>\n

<\/td>\n\n

\nTaylor, A. W. et al. Initial findings from a novel population-based child mortality surveillance approach: a descriptive study. Lancet Glob Health 8, e909-e919 (2020). https:\/\/doi.org:10.1016\/S2214-109X(20)30205-9<\/a>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n2\n<\/p>\n<\/td>\n

<\/td>\n\n

\nKlebsiella pneumoniae in Healthcare Settings, <https:\/\/www.cdc.gov\/hai\/organisms\/klebsiella\/klebsiella.html<\/a>> (2010).\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n3\n<\/p>\n<\/td>\n

<\/td>\n\n

\nAntimicrobial Resistance, C. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629-655 (2022). https:\/\/doi.org:10.1016\/S0140-6736(21)02724-0<\/a>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n4\n<\/p>\n<\/td>\n

<\/td>\n\n

\nFeldman, M. F. et al. A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae. Proc Natl Acad Sci U S A 116, 18655-18663 (2019). https:\/\/doi.org:10.1073\/pnas.1907833116<\/a>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n\u00a0\n<\/p>\n

Contacts<\/b> <\/p>\n

\nTimothy Cooke
\n
Chief Executive Officer
\n
media@omniose.com<\/a>
www.omniose.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON & ST. LOUIS–(BUSINESS WIRE)–Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, has been awarded a $3.6 million grant for the development of a Klebsiella pneumoniae vaccine from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health. Klebsiella pneumoniae is a leading cause of life-threatening sepsis … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49467","6":"format-standard","7":"category-industry"},"yoast_head":"\nOmniose Awarded $3.6 Million Grant from NIH to Develop Vaccines against Klebsiella pneumoniae - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Omniose Awarded $3.6 Million Grant from NIH to Develop Vaccines against Klebsiella pneumoniae - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON & ST. LOUIS–(BUSINESS WIRE)–Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, has been awarded a $3.6 million grant for the development of a Klebsiella pneumoniae vaccine from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health. Klebsiella pneumoniae is a leading cause of life-threatening sepsis ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-11T09:02:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221011005129\/en\/1596144\/21\/Omniose_Logo_CMYK.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Omniose Awarded $3.6 Million Grant from NIH to Develop Vaccines against Klebsiella pneumoniae\",\"datePublished\":\"2022-10-11T09:02:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\\\/\"},\"wordCount\":472,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005129\\\/en\\\/1596144\\\/21\\\/Omniose_Logo_CMYK.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\\\/\",\"name\":\"Omniose Awarded $3.6 Million Grant from NIH to Develop Vaccines against Klebsiella pneumoniae - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005129\\\/en\\\/1596144\\\/21\\\/Omniose_Logo_CMYK.jpg\",\"datePublished\":\"2022-10-11T09:02:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005129\\\/en\\\/1596144\\\/21\\\/Omniose_Logo_CMYK.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005129\\\/en\\\/1596144\\\/21\\\/Omniose_Logo_CMYK.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Omniose Awarded $3.6 Million Grant from NIH to Develop Vaccines against Klebsiella pneumoniae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Omniose Awarded $3.6 Million Grant from NIH to Develop Vaccines against Klebsiella pneumoniae - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/","og_locale":"en_US","og_type":"article","og_title":"Omniose Awarded $3.6 Million Grant from NIH to Develop Vaccines against Klebsiella pneumoniae - Pharma Trend","og_description":"BOSTON & ST. LOUIS–(BUSINESS WIRE)–Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, has been awarded a $3.6 million grant for the development of a Klebsiella pneumoniae vaccine from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health. Klebsiella pneumoniae is a leading cause of life-threatening sepsis ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-11T09:02:00+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221011005129\/en\/1596144\/21\/Omniose_Logo_CMYK.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Omniose Awarded $3.6 Million Grant from NIH to Develop Vaccines against Klebsiella pneumoniae","datePublished":"2022-10-11T09:02:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/"},"wordCount":472,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221011005129\/en\/1596144\/21\/Omniose_Logo_CMYK.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/","url":"https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/","name":"Omniose Awarded $3.6 Million Grant from NIH to Develop Vaccines against Klebsiella pneumoniae - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221011005129\/en\/1596144\/21\/Omniose_Logo_CMYK.jpg","datePublished":"2022-10-11T09:02:00+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221011005129\/en\/1596144\/21\/Omniose_Logo_CMYK.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221011005129\/en\/1596144\/21\/Omniose_Logo_CMYK.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/omniose-awarded-3-6-million-grant-from-nih-to-develop-vaccines-against-klebsiella-pneumoniae\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Omniose Awarded $3.6 Million Grant from NIH to Develop Vaccines against Klebsiella pneumoniae"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49467"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49467\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49467"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49467"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}